Retina

The trial results show promising for the evaluated gene therapy for the treatments of LCA, showing significant vision improvements in pediatric patients.

Miere discusses retinal studies on AMD and vein occlusion, highlighting imaging advancements and the future of machine learning in treatment predictions.

Explore the Fight Retinal Blindness! Project, a global registry enhancing VEGF inhibitor treatment outcomes with comprehensive data and insights for better patient care.

Explore how digital image management and AI transform ophthalmology, enhancing diagnostics and personalizing patient care in retina practices.

Subramanian discusses how subtle retinal and optic nerve findings can point to underlying neurologic disease.

In honor of looking back at 50 years, we look forward at a world where the toughest eye diseases could be cured in the blink of an eye.

Research on methotrexate's role in PVR retinal detachment surgery shows promising visual improvements, potentially transforming treatment strategies in ophthalmology.

EYLUXVI (ALT-L9) is an aflibercept (Eylea) biosimilar from Alteogen, co-developed by its subsidiary, Alteogen Biologics.

The submission was based on the safety and efficacy data from the phase 3 (RHODOS) and phase 4 (LEROS) studies.

The partnership was announced in August of this year.

EURETINA's 25th anniversary meeting attracts 11,000 participants, showcasing cutting-edge research, networking opportunities, and empowering women in retina.

Discover new insights into central serous chorioretinopathy, including pathophysiology, imaging techniques, and effective treatment options for better patient outcomes.

Mark your calendars: On September 26 and 27, 2025, the Ophthalmology Times and Optometry Times EyeCon 2025 conference will convene at the Margaritaville Hollywood Beach Resort in Hollywood, Florida.

The studies compared the Unity Vitreoretinal Cataract System (VCS) to the Constellation Vision System and the Centurion Vision System with Active Sentry.

Belite Bio completes its phase 3 trial for tinlarebant, a potential first treatment for Stargardt disease, with results expected in late 2025.

Kwangdong, a top 5 pharmaceutical and healthcare company in Korea, is actively involved in research and development innovation, including “transformational late-stage, high-impact technologies.”